0008-0000-22-072-H01-P Release 08/18/2022 Expires 08/18/2025.

With the expansion of access to Cannabis products in many states without the oversight of a health care provider, patients are more often counseled by retail staff. The relevance of this instructional module is that it will provide the participant with the background on the medical history of Cannabis and the pharmacology of its chemical constituents to authoritatively discuss the product with patients.

Learn More

0008-0000-22-073-H01-P Release 08/18/2022 Expires 08/18/2025.

The cannabinoids are not readily derived from the Cannabis plant. They need to be extracted and are increasingly provided in dosage forms that patients find more tolerable than smoking.  Each dosage form has unique characteristics that influence where, how much and how quickly of the compound gets into the body, how long the effects last, and the adverse effects experienced.  Patients need assistance understanding these characteristics and how their choices may mitigate or minimize adverse effects. 

Learn More

0008-0000-22-074-H01-P Release 08/18/2022 Expires 08/18/2025.

This module provides some experiential information on evaluating patients who are using cannabis or are interested in using cannabis and focuses on mental health conditions. Literature discussing safety and efficacy of more common mental health conditions is discussed and a clinical interpretation is provided. This information is relevant for all health professionals who interact with patients with mental health conditions in any capacity. It aims to inform the health professional regarding safety and efficacy of cannabis with notes on clinical application of this knowledge with a risk reductive strategy and goal of improved health outcomes.

Learn More

0008-0000-22-075-H01-P Release 08/18/2022 Expires 08/18/2025.

Over the past several years, there has been a growing interest in using medicinal cannabis to treat certain neurological conditions. Much debate has occurred over which cannabinoids may provide evidence-based or anecdotal relief for a variety of symptoms. In this module we will explore available literature and investigate real-world clinical use in epilepsy and movement disorders.

Learn More

0008-0000-22-076-H01-P Release 08/18/2022 Expires 08/18/2025.

In this module we will critically evaluate the available literature with medicinal cannabis in the treatment or symptomatic relief of sleep disorders, migraines, and multiple sclerosis. This module will also discuss clinical experience and hear from a patient’s perspective. Although the focus is neurology disease states, some of the symptomatology discussed is relevant to other disease states that may be encountered in the real world.

Learn More

0008-0000-22-077-H01-P Release 08/18/2022 Expires 08/18/2025.

This module will cover the most common indication patients seek treatment with medical cannabis.... pain.  Not only is this the most common reason for medical cannabis use among the general population, it is also the most common reason cancer patients use this product.  Cancer patients also use medical cannabis for relief from a variety of symptoms related to their disease and treatment such as nausea/vomiting, weight loss, and insomnia.  It is important that health care practitioners are aware of the evidence surrounding these common indications as well as safe use of medical cannabis.

Learn More

0008-0000-22-078-H01-P Release 08/18/2022 Expires 08/18/2025.

Beneficence and nonmaleficence are two important ethical principles in the healthcare professions. These principles require healthcare professionals to weigh the benefits and risks of treatment, and specifically for this course, the benefits, and risks of medical cannabis use. As patients play a more active role in their treatment decisions and may choose to use medical cannabis with or without a prescription or recommendation, healthcare professionals need to be adequately prepared to discuss the benefits and risks of medical cannabis use, potential drug interactions, and the safety of cannabis products.

The risks of medical cannabis use may be higher in certain populations, including adolescents, pregnant and lactating women, and advanced age patients. Furthermore, patients taking other concurrent medications while using medical cannabis may be at risk for significant drug interactions. Therefore, it is critical to gain an understanding about why these atrisk or vulnerable populations may need special attention. Additionally, patient safety concerns exist regarding the quality and purity of products because there is widespread availability, and they have disparate regulations. This module will highlight how healthcare professionals can help patients make informed decisions about cannabis use as it relates to benefits, risks, and product quality.

Learn More

0008-0000-22-079-H01-P Release 08/18/2022 Expires 08/18/2025.

Though there is tremendous interest in Cannabis products, there is significant variability across states regarding availability and regulation.  The relevance of this instructional module is that it will provide the participant with the background on Cannabis regulation at both the state and federal level, and initiatives by the FDA to provide the regulatory framework for CBD-containing products.

Learn More